Helperby Therapeutics announces phase 1 results demonstrating multiple benefits of its unique combination antibiotic therapy - effective against the WHO Critical Priority Carbapenem resistantbacterial pathogens

April 21, 2018
Helperby Therapeutics Ltd

[ECCMID, Madrid, 21st April 2018] Helperby Therapeutics Ltd (Helperby) has presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) announcing Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.

PR available here: